Abemaciclib inotenderwa neFDA ine endocrine kurapwa kwekutanga kenza yemazamu

Share This Post

October 2021: Kudya neDrug Administration kwave kubvumidza abemaciclib (Verzenio, Eli Lilly uye Kambani) pamwe chete ne endocrine therapy (tamoxifen kana aromatase inhibitor) ye adjuvant kurapwa kwevarwere vakuru vane hormone receptor (HR) -positive, human epidermal growth factor receptor 2 (HER2) -negative, node-positive, kenza yemazamu yekutanga panjodzi huru kudzokorora uye chibodzwa cheKi-67 chisingasviki makumi maviri muzana, sekutsanangurwa neFDA- Iyi ndiyo yekutanga CDK 20/4 inhibitor kubvumidzwa kurapwa kwegomarara rezamu.

Agilent, Inc. yakaendesa Ki-67 IHC MIB-1 pharmDx (Dako Omnis) assay, iyo yakabvumirwa neFDA semufambisi wekuongorora kwechiratidzo ichi.

Vakadzi vakuru nevarume vane HR-positive, HER2-negative, node-positive, resected, kenza yemazamu yekutanga ine kliniki uye pathological hunhu hunoenderana nenjodzi huru yekudzoka kwechirwere vaibatanidzwa mu monarchE (NCT03155997), a randomized (1: 1) , open-label, two-cohort multicenter muyedzo. Varwere vakapihwa angave makore maviri eabemaciclib pamwe nesarudzo yachiremba yavo yeyakajairwa endocrine mushonga kana yakajairika endocrine therapy chete.

Invasive chirwere-isina kupona yaive yekutanga mhedzisiro mhedzisiro chiyero (IDFS). Muedzo wakawana kuvandudzwa kwenhamba muIDFS (HR 0.626; 95 muzana CI: 0.488, 0.803; p = 0.0042) kune varwere vane njodzi huru yekudzoka uye Ki-67 Score isingasviki 20% (N = 2003). Varwere vaigamuchira abemaciclib ne tamoxifen kana aromatase inhibitor vaiva neIDFS ye86.1 muzana (95 muzana CI: 82.8, 88.8) mumwedzi ye36, asi avo vanogamuchira tamoxifen kana aromatase inhibitor vaiva neIDFS ye79.0 muzana (95 muzana 75.3. ) Panguva yekuongorora kweIDFS, data rese rekupona rakanga risati rakwana.

Manyoka, zvirwere, neutropenia, kuneta, leukopenia, kusvotwa, kupererwa neropa, uye kutemwa nemusoro ndizvo zvainyanya kuitika (20%).

Iyo yakakurudzirwa yekutanga dose yeabemaciclib ndeye 150 mg kaviri zuva nezuva pamwe chete netamoxifen kana aromatase inhibitor kwemakore maviri kana kusvika chirwere chekudzoka kana huturu husingaregi, chero hupi hunouya pakutanga.

Subscribe To Newsletter Vedu

Wana zvigadziriso uye usambopotsa blog kubva kuCancerfax

Zvimwe Kuti Uongorore

Kunzwisisa Cytokine Release Syndrome: Zvinokonzera, Zviratidzo, uye Kurapa
CAR T-Cell kurapa

Kunzwisisa Cytokine Release Syndrome: Zvinokonzera, Zviratidzo, uye Kurapa

Cytokine Release Syndrome (CRS) is immune system reaction inowanzo kukonzerwa nemamwe marapirwo senge immunotherapy kana CAR-T cell therapy. Zvinosanganisira kuburitswa kwakanyanya kwemacytokines, zvichikonzera zviratidzo kubva pafivha uye kuneta kusvika kune zvinogona kuuraya hupenyu sekukuvadzwa kwenhengo. Kutungamira kunoda kunyatsotarisisa uye nzira dzekupindira.

Basa revaparamedics mukubudirira kweCAR T Cell therapy
CAR T-Cell kurapa

Basa revaparamedics mukubudirira kweCAR T Cell therapy

Paramedics inobata basa rakakosha mukubudirira kweCAR T-cell therapy nekuona kuchengetwa kwemurwere pasina musono panguva yese yekurapa. Vanopa rubatsiro rwakakosha panguva yekufambisa, kutarisa zviratidzo zvinokosha zvevarwere, uye kupa rubatsiro rwechimbichimbi kana matambudziko amuka. Kupindura kwavo nekukurumidza uye kutarisirwa kwehunyanzvi kunobatsira mukuchengetedzeka kwese uye kushanda kwekurapa, kufambisa shanduko yakapfava pakati pezvirongwa zvehutano uye kuvandudza mhedzisiro yevarwere munzvimbo yakaoma yemhando yepamusoro cellular therapies.

Kuda rubatsiro? Chikwata chedu chakagadzirira kukubatsira.

Tinoshuvira kupora nekukurumidza kwemudiwa wako uye padyo neuyo.

Kutanga kutaura
Tiri paIndaneti! Taura Nesu!
Skena kodhi
Mhoro,

Kugamuchirwa kuCancerFax!

CancerFax ipuratifomu yekupayona yakatsaurirwa kubatanidza vanhu vakatarisana negomarara repamberi nekurapa kwesero seCAR T-Cell therapy, TIL kurapwa, uye miedzo yekiriniki pasi rese.

Tizivise zvatinogona kukuitira.

1) Kurapwa kwegomarara kunze kwenyika?
2) CAR T-Cell therapy
3) Mushonga wegomarara
4) Online vhidhiyo kubvunza
5) Proton kurapwa